Anti-interleukin-2 receptor monoclonal antibody NDS61

Drug Profile

Anti-interleukin-2 receptor monoclonal antibody NDS61

Alternative Names: Anti-CD25 monoclonal antibody NDS61; Interleukin-2 receptor monoclonal antibody NDS61; NDS61

Latest Information Update: 19 Nov 2003

Price : $50

At a glance

  • Originator University of Wuerzburg
  • Developer Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 19 Nov 2003 Discontinued - Preclinical for Transplant rejection in Germany (unspecified route)
  • 12 Oct 1998 Preclinical development for Transplant rejection in Germany (Unknown route)
  • 12 Oct 1998 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top